TY - JOUR
T1 - Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes
AU - Urbańczyk, Kamila
AU - Guntschnig, Sonja
AU - Antoniadis, Vasilis
AU - Falamic, Slaven
AU - Kovacevic, Tijana
AU - Kurczewska-Michalak, Marta
AU - Miljković, Branislava
AU - Olearova, Anna
AU - Sviestina, Inese
AU - Szucs, Attila
AU - Tachkov, Konstantin
AU - Tiszai, Zita
AU - Volmer, Daisy
AU - Wiela-Hojeńska, Anna
AU - Fialova, Daniela
AU - Vlcek, Jiri
AU - Stuhec, Matej
AU - Hogg, Anita
AU - Scott, Michael
AU - Stewart, Derek
AU - Mair, Alpana
AU - Ravera, Silvia
AU - Lery, François-Xavier
AU - Kardas, Przemysław
N1 - Funding Information:
We would like to acknowledge the input of other representatives from different countries who helped in gathering the data and were not directly involved in manuscript preparation.
Publisher Copyright:
Copyright © 2023 Urbańczyk, Guntschnig, Antoniadis, Falamic, Kovacevic, Kurczewska-Michalak, Miljković, Olearova, Sviestina, Szucs, Tachkov, Tiszai, Volmer, Wiela-Hojeńska, Fialova, Vlcek, Stuhec, Hogg, Scott, Stewart, Mair, Ravera, Lery and Kardas.
PY - 2023/8/2
Y1 - 2023/8/2
N2 - Clinical pharmacy as an area of practice, education and research started developing around the 1960s when pharmacists across the globe gradually identified the need to focus more on ensuring the appropriate use of medicines to improve patient outcomes rather than being engaged in manufacturing and supply. Since that time numerous studies have shown the positive impact of clinical pharmacy services (CPS). The need for wider adoption of CPS worldwide becomes urgent, as the global population ages, and the prevalence of polypharmacy as well as shortage of healthcare professionals is rising. At the same time, there is great pressure to provide both high-quality and cost-effective health services. All these challenges urgently require the adoption of a new paradigm of healthcare system architecture. One of the most appropriate answers to these challenges is to increase the utilization of the potential of highly educated and skilled professionals widely available in these countries, i.e., pharmacists, who are well positioned to prevent and manage drug-related problems together with ensuring safe and effective use of medications with further care relating to medication adherence. Unfortunately, CPS are still underdeveloped and underutilized in some parts of Europe, namely, in most of the Central and Eastern European (CEE) countries. This paper reviews current situation of CPS development in CEE countries and the prospects for the future of CPS in that region.
AB - Clinical pharmacy as an area of practice, education and research started developing around the 1960s when pharmacists across the globe gradually identified the need to focus more on ensuring the appropriate use of medicines to improve patient outcomes rather than being engaged in manufacturing and supply. Since that time numerous studies have shown the positive impact of clinical pharmacy services (CPS). The need for wider adoption of CPS worldwide becomes urgent, as the global population ages, and the prevalence of polypharmacy as well as shortage of healthcare professionals is rising. At the same time, there is great pressure to provide both high-quality and cost-effective health services. All these challenges urgently require the adoption of a new paradigm of healthcare system architecture. One of the most appropriate answers to these challenges is to increase the utilization of the potential of highly educated and skilled professionals widely available in these countries, i.e., pharmacists, who are well positioned to prevent and manage drug-related problems together with ensuring safe and effective use of medications with further care relating to medication adherence. Unfortunately, CPS are still underdeveloped and underutilized in some parts of Europe, namely, in most of the Central and Eastern European (CEE) countries. This paper reviews current situation of CPS development in CEE countries and the prospects for the future of CPS in that region.
KW - clinical pharmacy
KW - cost-effective treatment
KW - health policy
KW - medication adherence
KW - drug safety
KW - medication errors
KW - drug utilization
KW - polypharmacy
UR - https://www.scopus.com/pages/publications/85168282722
U2 - 10.3389/fphar.2023.1244151
DO - 10.3389/fphar.2023.1244151
M3 - Article
C2 - 37601045
SN - 1663-9812
VL - 14
SP - 1
EP - 16
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
M1 - 1244151
ER -